Actuate Therapeutics presented data at ASCO 2026 showing that elraglusib, combined with gemcitabine/Abraxane or FOLFIRINOX, significantly improves median overall survival in patients with metastatic pancreatic ductal adenocarcinoma, especially those with wild-type KRAS and TP53 genes. The treatment was well tolerated and showed deep, durable responses, suggesting elraglusib's potential as a backbone therapy in combination with existing chemotherapy. Future plans include developing an oral formulation to expand treatment options and patient populations.
Kinross Gold Corporation published its 2025 Sustainability Report showcasing its commitment to responsible mining through significant economic contributions of $4.9 billion to host countries and strong performance in environmental, social, and govern...
Hewlett Packard Enterprise (HPE) shares surged over 7% in premarket trading, reaching a new 52-week high as investors anticipate the company's Q2 earnings report due after market close on June 1. Analysts expect earnings per share of 54 cents, up 42%...
US stock futures rose following weekend US strikes in Iran targeting radar and command sites in response to aggressive Iranian actions, including the downing of a US drone. The S&P 500 ended May at a record high, supported by strong performances in t...
Auddia Inc. announced a 12-month partnership between its AI-driven Discovr Radio platform and Beatcave, Canada's leading independent music community. Discovr Radio becomes Beatcave's official membership partner, offering independent artists guarantee...
Heineken N.V. has repurchased a total of 3,192,296 shares under the second €750 million tranche of its €1.5 billion share buyback program, spending €219.6 million as of May 29, 2026. The shares were bought both on the exchange and from Heineken Holdi...
